Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (620), Birmingham, Alabama +88 locations
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Recruiting
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Atea Study Site, Birmingham, Alabama +72 locations
Conditions: HEPATITIS C VIRUS CHRONIC INFECTION
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Recruiting
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Bay Pines, Florida +179 locations
Conditions: Carcinoma, Non-Small Cell Lung
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2025
Locations: Research Site, Cullman, Alabama +257 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
Recruiting
Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes. Study Design Type This is a multi-center, open-label, parallel-group, individual randomized controlled trial comparing two different trophic feeding regimens in preterm infants born between 25w0d and 31w6d. These... Read More
Gender:
ALL
Ages:
Between 0 hours and 36 hours
Trial Updated:
07/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +5 locations
Conditions: Sepsis, Length of Stay, Mortality
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix, Arizona +4 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Primary Care-based Study of an Online Workshop for Family Caregivers of PLWD
Recruiting
Many family and friend caregivers of persons living with dementia experience depression, stress, and other adverse health consequences due to the responsibilities of their caregiving role. These caregivers express a desire for education and support. The overarching goal of this project is to improve education and support for caregivers of persons living with dementia so that they can take better care of themselves and also their person living with dementia. Building Better Caregivers workshop i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Family Caregivers, Dementia, Self-management, Depression, Internet-based Intervention
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Recruiting
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Gender:
ALL
Ages:
Between 0 years and 29 years
Trial Updated:
07/23/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Pilot Study of App-delivered Sleep Coaching Among Cancer Survivors and Their Partners
Recruiting
The proposed study will test the feasibility and acceptability of enrolling and retaining cancer survivors and their bedroom partners in a study evaluating digitally delivered behavioral sleep interventions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Cancer
Alesis OSA-1 Obstructive Sleep Apnea Treatment
Recruiting
The goal of randomized clinical trial is to determine if the Alesis OSA-1 low laser light therapy device can reduce apnea-hypopnea index scores and treat sleep apnea in adult participants over the age of 18 who are diagnosed with obstructive sleep apnea (OSA). The main questions it aims to answer are\]: • Does the use of the Alesis OSA-1 device reduce the number of AHI events after six treatments of 12 minutes each, 2x per week x 3 weeks, in adult OSA patients? Researchers will compare results... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: JD Medical Group, LLC, Miami, Florida +1 locations
Conditions: Obstructive Sleep Apnea
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Recruiting
The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Research Site, Aurora, Colorado +11 locations
Conditions: IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
Recruiting
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma